A clinical trial in patients with advanced breast cancer has found the use of liquid biopsy blood tests for early detection of a treatment-resistant mutation, followed by a new type of treatment, substantially extends the period of tumor control.
The gift from philanthropist Tom Secunda, co-founder of Bloomberg L.P., will help fund artificial intelligence-related research at Cornell Tech in New York City and at the Cornell Ann S. Bowers College of Computing and Information Science in Ithaca.
A team of Cornell researchers is exploring how workplace tracking apps can be used not to surveil workers, but to help them build solidarity and improve their working conditions.
Linda Gadsby ’88 will be honored by the ILR School at its annual Groat & Alpern Celebration recognizing top alumni on April 24 at The Pierre in New York City.
The new Startup Cornell podcast episode features Van Hamilton Barbeau '11, MS/MBA '20, AVP at Ochsner Ventures, the venture capital arm of Ochsner Health.
A new artificial intelligence-based method accurately sorts cancer patients into groups that have similar characteristics before treatment and similar outcomes after treatment, according to a study led by investigators at Weill Cornell Medicine.
Researchers at Weill Cornell Medicine have discovered that a parasite that causes malaria when transmitted through a mosquito bite can shut down a key set of genes, rendering itself “immunologically invisible” — sometimes for years.
Weill Cornell Medicine has received a projected $4 million grant to conduct a clinical trial testing whether a new imaging approach could reduce the need for biopsies to monitor prostate cancer.
Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.